The complaint, filed by the law firm Glancy Prongay Wolke & Rotter LLP, alleges that Procept misled shareholders by utilizing an aggressive discount program. This scheme reportedly incentivized customers to place bulk handpiece orders that far exceeded actual medical procedure demand. Prosecutors claim this practice allowed the company to pull future sales forward, creating a facade of unsustainable growth while masking an accumulation of over 10,000 excess units in field inventory.
Procept BioRobotics Faces Securities Fraud Class Action Over Sales Tactics
Investors who incurred financial losses from Procept BioRobotics Corporation stock between February 2024 and February 2026 have until September 22, 2026, to apply as lead plaintiffs in a newly filed securities fraud class action lawsuit centered on alleged artificial inflation of revenue.
According to the legal filing, these undisclosed inventory surpluses resulted in materially misleading financial statements regarding the company's operational health. By failing to disclose the true nature of these sales incentives, defendants allegedly masked significant financial risks from the market. Shareholders seeking to participate in the litigation or act as lead plaintiffs must contact the firm or file with the court before the September 22 deadline. No class has been certified at this stage, and investors retain the right to select their own counsel or remain as absent class members.
Comments (0)
No comments yet. Be the first!